Cardiovascular Outcomes Trial

Our cardiovascular outcomes trial, known as CLEAR Outcomes, met its primary endpoint, demonstrating statistically significant and clinically meaningful results.

CLEAR Outcomes Study

The primary endpoint was achieved.
Focused on significant, underserved population unable to maximize or tolerate statins
Nearly 14,000 patients in 32 countries
Nearly half of the patients were women

Primary Endpoint (MACE-4)

Composite of the time to first cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization

Hierarchy of Secondary Endpoints

  • Composite of death from cardiovascular causes, nonfatal MI and non fatal stroke
  • Fatal and nonfatal MI
  • Coronary revascularization
  • Fatal and nonfatal stroke
  • Death from cardiovascular causes
  • All-cause mortality

The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined.